Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

2020628 citationsJournal Articlebronze Open Access

Authors

John R. Teerlink · San Francisco VA Medical Center

Rafael Díaz · San Francisco VA Medical Center

G. Michael Felker · San Francisco VA Medical Center

John J.V. McMurray · San Francisco VA Medical Center

Marco Metra · San Francisco VA Medical Center

Scott Solomon · Brigham and Women's Hospital

Kirkwood F. Adams

Abstract

Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016-002299-28.).

Topics & Keywords

Cardiovascular Function and Risk Factors Diabetes Treatment and Management Cardiac pacing and defibrillation studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 384, Issue 2, pp. 105-116

DOI: 10.1056/nejmoa2025797

Field-Weighted Citation Impact: 66.90